AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 535145
Drug: Radical radiotherapy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiotherapy and/or chemotherapy
Trial: 535145
Drug: Serial determinations
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial determinations post-treatment
Trial: 31531552
Drug: self‐etch/bulk‐fill in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐etch/bulk‐fill in capsules
Trial: 31531552
Drug: selective enamel‐etching/bulk‐fill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selective enamel‐etching/bulk‐fill in capsules
Trial: 31531552
Drug: bulk‐fill composite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bulk‐fill composite (capsules or syringes)
Trial: 25048310
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone (4 mg/kg/day)
Trial: 25048310
Drug: Usual-dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual-dose prednisolone (2 mg/kg/day)
Trial: 22351891
Drug: Amoxicillin (post-CPG)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (post-CPG)
Trial: 22351891
Drug: Cefdinir and
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir and amoxicillin/clavulanate (post-CPG)
Trial: 19483319
Drug: Kampo preparation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kampo preparation, byakkokaninjinto (TJ‐34)
Trial: 12377966
Drug: G17DT 250
RxNorm normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G17DT 250 micro g
Trial: 12377966
Drug: G17DT 100
RxNorm normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G17DT 100 micro g
Trial: 12377966
Drug: G17DT (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G17DT (both doses)
Trial: 9881078
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salvage therapy and high dose chemo(radio)‐therapy with stem cell support
Trial: 338256
Drug: Bumetanide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (mean 1.3 mg/day, doses varied from 1 mg on alternate days to 3 mg daily)
Trial: 338256
Drug: Frusemide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (mean 72 mg/day, doses varied from 40 mg on alternate days to 160 mg daily)
Trial: 30897068
Drug: Oral spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral spironolactone (SPRL)
Trial: 29652086
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment after open surgery
Trial: 29652086
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment after EVLA
Trial: 29652086
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment after UGFS
Trial: 29652086
Drug: UGFS without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UGFS without further GSV treatment
Trial: 28471726
Drug: blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blended cognitive behavior therapy (bCBT)
Trial: 25297344
Drug: Caffeine (400 mg)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (400 mg)
Trial: 21981455
Drug: Intravenous phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phenylephrine (PE) infusion
Trial: 10966544
Drug: Pilsicainide 150
RxNorm normalized name: Pilsicaïnide
DrugBank: Pilsicainide (DB12712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilsicainide 150 mg/day for 4 weeks before electrical cardioversion
Trial: 10966544
Drug: Pilsicainide 150
RxNorm normalized name: Pilsicaïnide
DrugBank: Pilsicainide (DB12712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilsicainide 150 mg/day after successful cardioversion
Trial: 8888359
Drug: ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (0.15 mg/kg, i.v.)
Trial: 1310889
Drug: Intra-arterial cisplatin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered concomitant with radiation therapy
Trial: 1310889
Drug: Intra-arterial cisplatin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered sequentially with radiation therapy
Trial: 1310889
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment arm
Trial: 1310889
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy arm
Trial: 6380363
Drug: Cefuroxime plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime plus metronidazole (1.5 g cefuroxime plus 500 mg metronidazole)
Trial: 6380363
Drug: Metronidazole alone
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole alone (500 mg metronidazole)
Trial: 31636065
Drug: GLS4 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS4 120 mg with ritonavir 100 mg
Trial: 31636065
Drug: GLS4 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS4 alone (multiple dosing)
Trial: 31636065
Drug: GLS4 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS4 240 mg with ritonavir 100 mg (placebo control)
Trial: 31636065
Drug: GLS4 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS4 240 mg (single and multiple doses)
Trial: 30149375
Drug: Voice exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice exercises with water resistance therapy at 4 and 8 cm of water depth
Trial: 30149375
Drug: Voice exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice exercises with water resistance therapy at 8 cm
Trial: 26267328
Drug: 200 μg selenium
RxNorm normalized name: SELENIUM 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg selenium daily for 8 weeks
Trial: 14687451
Drug: Ibuprofen/pseudoephedrine modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/pseudoephedrine modified-release capsule (600 mg ibuprofen + 90 mg pseudoephedrine)
Trial: 14687451
Drug: Standard formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulations of ibuprofen (400 mg) and pseudoephedrine (60 mg)
Trial: 14687451
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing of the slow-release formulation
Trial: 26546386
Drug: Nintendo Wii
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nintendo Wii IGC, 5 days of twice daily, 20‐30 min of exercise
Trial: 26546386
Drug: Routine rehabilitation
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rehabilitation exercise therapy
Trial: 24434382
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg twice a day)
Trial: 22067763
Drug: Low-dose 91-day
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 91-day extended regimen of 100 mcg levonorgestrel/20 mcg ethinyl estradiol (LNG/EE; 84 days)+10 mcg EE (7 days)
Trial: 10065682
Drug: Low-dose erythromycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose erythromycin (500 mg b.i.d.) for 8 weeks
Trial: 8828358
Drug: Rhubarb (1.0g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb (1.0g administered orally)
Trial: 29327047
Drug: Honey gel
RxNorm normalized name: DRESSING,HONEY GEL,TOP
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey gel
Trial: 19945274
Drug: High-dose epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epidural (0.25% bupivacaine)
Trial: 12388962
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (25 micrograms every 4 hours up to six doses)
Trial: 12388962
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline solution infusion with oxytocin
Trial: 7751531
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (IB) 84 micrograms (two sprays of a 0.06% solution in buffered saline solution)
Trial: 7751531
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (IB) 42 micrograms per nostril
Trial: 7751531
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (IB) 168 micrograms per nostril
Trial: 7751531
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (IB) 84 micrograms per nostril
Trial: 7751531
Drug: Vehicle or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle or no treatment
Trial: 6587757
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg thrice daily)
Trial: 30278429
Drug: 3.6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g/d ALA plus 190 mg/d quercetin
Trial: 29194917
Drug: Exenatide (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (once-weekly extended-release subcutaneous)
Trial: 25201358
Drug: FOLFOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil bolus 400 mg/m(2) on day 1, and fluorouracil infusion 2400 mg/m(2) for 46 h, every 2 weeks)
Trial: 25201358
Drug: Fluorouracil and
RxNorm normalized name: Fluorouracil and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil and leucovorin (fluorouracil 380 mg/m(2) and leucovorin 20 mg/m(2) on days 1-5, every 4 weeks)
Trial: 20506674
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg per day from day 3 to day 7 of the cycle
Trial: 20506674
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg per day on the same cycle days
Trial: 11966868
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.i.d. plus tetracycline 500 mg q.i.d. with lansoprazole 30 mg b.i.d. for 7 days (group LAT)
Trial: 11966868
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.i.d. plus tetracycline 500 mg q.i.d. with ranitidine bismuth citrate 400 mg b.i.d. for 7 days (group RBCAT)
Trial: 11966868
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.i.d. plus doxycycline 100 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days (group LAD)
Trial: 7772357
Drug: Succinylcholine (S)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (S) 1 mg/kg
Trial: 7772357
Drug: Rocuronium (R)
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium (R) 600 mcg/kg
Trial: 7772357
Drug: Rocuronium (R)
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium (R) 150 mcg/kg (open label)
Trial: 341951
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg four times daily)
Trial: 341951
Drug: Erythromycin with
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin with sulphametopyrazine (1 g at start of exacerbation followed by erythromycin 500 mg four times daily)
Trial: 28792952
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day (after crossover from placebo)
Trial: 19523672
Drug: Timothy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timothy extract monotherapy (19 microg Phl p 5 daily)
Trial: 3497039
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tenoxicam
Trial: 3497039
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tenoxicam
Trial: 28274268
Drug: True acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True acupuncture + metformin placebo
Trial: 28274268
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture + metformin
Trial: 28274268
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture + metformin placebo
Trial: 26158468
Drug: Appetitive solutions
RxNorm normalized name: APPETITE SUPPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appetitive solutions (juice)
Trial: 26158468
Drug: Aversive solutions
RxNorm normalized name: DRESSING,VERSIVA XC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aversive solutions (quinine)
Trial: 20031956
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (2.5 mg per patch)
Trial: 18400322
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment program following the cognitive orientation to daily occupational performance (CO-OP) approach
Trial: 12832240
Drug: Divalproex (500-2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex (500-2500 mg/day)
Trial: 6469823
Drug: Induced erythrocythemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced erythrocythemia (334 ml of red blood cells)
Trial: 22280502
Drug: Intermittent Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment in infants with Sulfadoxine‐Pyrimethamine (IPTi‐SP)
Trial: 12030736
Drug: Formoterol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (all doses)
Trial: 31805985
Drug: SPO2 system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPO2 system functionality, safety, efficacy, operating costs, nursing knowledge, skills, and retention for oxygen administration
Trial: 29309483
Drug: SB-TEAM program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-TEAM program (supervised administration of preventive asthma medication at school and 3 school-based telemedicine visits)
Trial: 26926910
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) plus Treatment as Usual (TAU) - up to 12 one-hour weekly sessions.
Trial: 26926910
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) alone.
Trial: 24436135
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (memantine + donepezil)
Trial: 23202836
Drug: Lead exposure
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead exposure in males (6.8 ± 2.0 µg/dL)
Trial: 23202836
Drug: Lead exposure
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead exposure in females (5.9 ± 1.9 µg/dL)
Trial: 23202836
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with BPb concentrations of 10 µg/dL or above
Trial: 19060628
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg immediate-release fluvastatin twice daily (b.i.d.)
Trial: 19060628
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg extended-release fluvastatin daily
Trial: 18090187
Drug: Premedication with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with diazepam 5-10 mg
Trial: 15144039
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (group A)
Trial: 15144039
Drug: Influenza and
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza and pneumococcus vaccines simultaneously (group B)
Trial: 11228086
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate aerosol (1.25 mg upon arrival and a second dose 15 minutes later if needed)
Trial: 11228086
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate (5 mg tablet)
Trial: 9972670
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of methimazole (MMI) and 20 g of colestipol‐hydrochloride (COL) daily
Trial: 9972670
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of MMI daily
Trial: 9972670
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of MMI and 20 g of COL daily
Trial: 8054260
Drug: Magnesium pidolate
RxNorm normalized name: magnesium pidolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium pidolate 4.5 g/d for one month
Trial: 3175536
Drug: Acarbose (Bay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (Bay g 5421)
Trial: 26698878
Drug: Ibuprofen 3
RxNorm normalized name: ibuprofen 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 3 × 400 mg for three days
Trial: 26698878
Drug: Fosfomycin 3
RxNorm normalized name: fosfomycin 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin 3 g (single dose) for three days
Trial: 17201265
Drug: Xuanju compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuanju compound capsule combined with erogenous focus exercise
Trial: 8446138
Drug: Diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120 to 360 mg per day)
Trial: 8446138
Drug: Atenolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25 to 100 mg per day)
Trial: 8446138
Drug: Clonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.2 to 0.6 mg per day)
Trial: 8446138
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 to 50 mg per day)
Trial: 8446138
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 to 100 mg per day)
Trial: 8446138
Drug: Prazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (4 to 20 mg per day)
Trial: 25792588
Drug: Gel pad
RxNorm normalized name: Zenphor Gel Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel pad application
Trial: 25792588
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel pad application (control)
Trial: 18633420
Drug: Motor physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor physical therapy (15 min daily, 5 times per week until discharge)
Trial: 12770975
Drug: topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical dorzolamide
Trial: 9601864
Drug: Spirapril 3
RxNorm normalized name: spirapril 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 3 mg or 6 mg
Trial: 9601864
Drug: Spirapril 12
RxNorm normalized name: spirapril 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 12 mg (small proportion of patients)
Trial: 9601864
Drug: Spirapril (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril (overall treatment)
Trial: 8224265
Drug: Flutamide 750
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide 750 mg/d
Trial: 8224265
Drug: Flutamide 500
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide 500 mg/d and 750 mg/d
Trial: 29120250
Drug: Nepafenac treatment
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nepafenac treatment (0.1%, three times/day)
Trial: 26642810
Drug: Lapatinib (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1250 mg) combined with Capecitabine (2000 mg/m2 on days 1 to 14)
Trial: 26642810
Drug: Lapatinib (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1250 mg) combined with Vinorelbine (25 mg/m2 on days 1 and 8)